Total Tumor Volume on 18 F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225 Ac-PSMA-I&T.
Lena M UnterrainerLeonie BeyerMathias J ZacherlFranz J GildehausAndrei TodicaSophie C KunteAdrien HolzgreveGabriel T SheikhAnnika HerlemannJozefina CasuscelliMatthias BrendelNathalie L AlbertVera WenterNina-Sophie Schmidt-HegemannWolfgang Gerhard KunzClemens C CyranJens RickeChristian G StiefPeter BartensteinHarun IlhanMarcus UnterrainerPublished in: Biomedicines (2022)
Ac-PSMA-RLT demonstrated drastic TTV decreases without direct correlation to other biomarkers, such as serum PSA changes. Changes in TTV might hence improve the response assessment compared to standard classifiers by reflecting the current tumor load independent of the occurrence of new lesions.